Immune Sera (Antisera)

05/07/2010 - "VPA1435, VP0764, VPA1186, VP1061, and VP2850 could be recognized by at least three antisera and demonstrated significantly passive and active immune protection against V. parahaemolyticus infection in a crucian carp model. "
05/15/1987 - "The passive transfer of P28 antisera induced a significant level of protection against experimental infection. "
09/18/2015 - "Primary infection antisera did not neutralize all viruses of the same DENV type any better than other types did up to 2 years after infection and did not show improved neutralization to homologous type isolates. "
06/01/1996 - "Antisera were observed to have protective effects when administered before and after acute lethal infection. "
09/01/1914 - "The distinctions in serum reactions between normal and para meningococci are supported by the differences in protective effects of the monovalent immune sera upon infection in guinea pigs and monkeys. "

12/01/2003 - "These studies showed no significant improvement indicating that combination therapy with anti-CD25(+) antisera requires LEC localization to tumor to produce complete regression. "
01/01/1987 - "None of the other antisera yielded positive results in tumors of either type. "
01/01/2005 - "The objective of this study was to begin to test this hypothesis by generating Mig-7 specific antisera and RT-PCR methods for detection of Mig-7 expression in tissues and blood from cancer patients as compared to those from normal subjects. "
04/20/2004 - "In additional studies in vivo, protective tumor immunity elicited by tumor-derived gp96-peptide complexes is shown to be abrogated by anti-CD91 antisera. "
01/01/2003 - "This study also shows the utility of tissue microarrays in the analysis of a large group of tumors with regionspecific antisera."

03/01/1976 - "The antisera are similar in activity to antisera raised following tolerance-induction with remission leukocytes, but larger volumes of anti-leukemia antiserum can be raised using the more easily obtainable platelets. "
01/01/1987 - "AAS prepared in congenic rat strains have shown the following pattern: alpha RT1 (MHC) AAS directed against RT1 antigenic specificities both "public" and "private" gave positive reactions with 100% of leukemia cells, all cross-reacting AAS directed against "public" specificities only, reacted positively too with 17-100% of leukemia cells and no alien specificities have been detected when LEW antisera were tested. "
01/01/1986 - "We prepared antisera to three distinct portions of the v-ets oncogene of the avian leukemia virus E26. "
01/01/1986 - "[Preparation and characterization of antisera specific to various polypeptide domains corresponding to the v-ets oncogene of the avian leukemia virus E26]."
01/01/1986 - "From T-cell cultures depleted of specific cell populations with monoclonal antisera, helper Lyt-1+ cells were shown to be responsible for permanent regressions (cures), whereas cytotoxic Lyt-2+ cells caused temporary leukemia remissions. "

08/01/1992 - "Anti-LOS antisera had minimal bactericidal activity and were not protective against the homologous strain in an infant rat model of bacteremia. "
01/01/1982 - "Previous studies in mice have demonstrated differing immunoprophylactic activity of antisera against rough mutants of Enterobacteriaceae in the prevention of lethal gram-negative bacteremia. "
12/01/2014 - "Immune sera were also tested for functional activity by in vitro opsonophagocytic-killing assays and a murine bacteremia model. "
01/01/2011 - "13-valent pneumococcal conjugate vaccine immune sera protects against pneumococcal serotype 1, 3, and 5 bacteremia in a neonatal rat challenge model."
04/01/2007 - "Moreover, the occurrence of bacteremia was prevented in infant rats by administration of immune sera before MenB challenge. "

07/01/1983 - "The passive protective efficacy of anti-live cell immune sera, derived from rabbits following recovery from experimental septicemia, was abolished through dual absorption with homologous O-cells. "
12/01/2002 - "Blood cultures of 6,956 patients (PUO/septicemia) were processed by standard procedures and the Salmonella spp. isolates were identified with specific antisera and with standard biochemical tests. "
07/01/1978 - "Experimental gram-negative bacterial sepsis: reevaluation of the ability of rough mutant antisera to protect mice."
11/01/2013 - "Blockade of CIRP using antisera to CIRP attenuated inflammatory cytokine release and mortality after hemorrhage and sepsis. "
07/01/1988 - "Polyclonal rabbit antisera were protective in the infant rat model of bacteremia/sepsis and facilitated killing of type II strains bearing the c protein in an in vitro opsonophagocytic bacterial killing assay. "